Browsing Tag
Eli Lilly
51 posts
One pen, four doses, one month: Eli Lilly brings Zepbound KwikPen to Ro’s telehealth platform at $299
Eli Lilly (LLY) partners with Ro to launch the FDA-approved Zepbound KwikPen nationwide. What the $299 self-pay device means for the GLP-1 race. Read more.
Lilly bets $7.8bn on orexin science with Centessa acquisition as neuroscience race intensifies
Eli Lilly agrees to acquire Centessa Pharmaceuticals for $6.3B, gaining orexin sleep drug cleminorexton. Read the full strategic analysis.
FDA approves Lilly’s Foundayo as second oral GLP-1 weight loss pill, challenging Novo Nordisk’s head start
FDA approves Eli Lilly's Foundayo (orforglipron), the second oral GLP-1 obesity pill with no food restrictions. What this means for LLY investors and patients. Read more.
Structure Therapeutics (Nasdaq: GPCR) posts 16% weight loss with oral GLP-1 drug aleniglipron, setting up Phase 3 push
Structure Therapeutics' aleniglipron hits 16% weight loss at 44 weeks in Phase 2, matching injectables. Read the full analysis before Phase 3 begins.
HIMS near 52-week low as FDA issues 30 GLP-1 warning letters
FDA sends 30 warning letters to GLP-1 compounders, targeting Hims & Hers Health (HIMS) as regulatory and legal pressure intensifies. Read what it means for investors and the sector.
Lilly’s Olumiant moves closer to European approval for teen alopecia patients as CHMP issues positive opinion
Eli Lilly's Olumiant wins CHMP backing for adolescent alopecia areata with 42% response rates — EU approval imminent, U.S. decision due late 2026. Read the full analysis.
Is dose escalation the new edge in the obesity drug war? Why GLP-1 rivals are raising the ceiling on efficacy
High-dose GLP-1 drugs like 7.2 mg Wegovy are redefining obesity treatment in 2025. Find out how dose escalation is shifting efficacy expectations.
Mangoceuticals lands breakthrough partnership with Eli Lilly and Novo Nordisk to deliver low-cost GLP-1 care
Find out how Mangoceuticals’ partnership with Eli Lilly and Novo Nordisk could transform affordable access to Zepbound and Wegovy obesity treatments.
Why Pfizer’s $10bn Metsera deal could reshape the obesity drug market in 2026 and beyond
Pfizer beats Novo Nordisk in $10B Metsera buyout, reshaping obesity drug competition. Find out what this means for the pharma M&A and GLP-1 space.
Why Viking Therapeutics (NASDAQ: VKTX) is gaining momentum before ObesityWeek 2025 reveals
Find out how Viking Therapeutics is positioning its obesity drug VK2735 for success as it readies data reveals at major 2025 medical conferences.